The virus is endemic to Central and South America where outbreaks in humans and equids have been reported in at least 12 countries. The mortality of VEEV in humans is lower than 1%, but neurological symptoms are seen in up to 14% of the infected persons.  Currently, there is no approved antiviral or vaccine for treatment or prevention of VEEV infections in humans.
